We are proud to present the SERCEB (Southeast Regional Center of Excellence for Emerging Infections and Biodefense) plan for the next five years of research, training and emergency response. Our organizing theme is "host-pathogen interactions: opportunities for intervention." We bring together an integrated and experienced team of superb investigators in virology, bacteriology, immunology, drug discovery and vaccine development whose ability to work together has been clearly demonstrated in the past five years. We believe our group is second to none, and look forward to the challenges and opportunities ahead with great confidence in our ability to deliver the highest quality discovery science, and in our ability to deliver clinically useful products. We work together in synergistic teams that span boundaries between universities, between basic scientists and public health workers,.and between academia and private enterprise. We are stronger by far than the sum of our individual parts. Our focus is in areas where our particular strengths add to or complement those of our partners throughout the national Regional Centers of Excellence (RCE) program. SERCEB is multidisciplinary team based in Region IV. The Prime Institution is the University of North Carolina Chapel Hill (UNC), and the other principal consortium members include Duke University, Emory University, Vanderbilt University, the University of Florida (Gainesville), and the University of Alabama at Birmingham. Our primary goal is to assist the nation in developing and deploying effective and rapid responses to biodefense and emerging infectious diseases threats. To this end, we will discover new therapies and principles by which effective new vaccines can be developed. Our pathways to discovery include better understanding of the pathogenic mechanisms by which pathogens cause disease and the nature of the immune responses against them. Hence, mechanistic studies on pathogenesis and animal models will also be a focus of study. We will concentrate on areas that offer promise for discovery of broad targets for therapy or prevention. We emphasize pathogen interactions with the innate immune system, an area of great SERCEB strength that offers excellent opportunities for discovery of broadly effective therapies. Discovery of new therapies also includes a focused screening and drug development team effort, which although not directly derived from studies of basic pathogenesis, depends in part on studies of pathogenesis to validate targets. Vaccine discovery is based on identification of crucial shared protective epitopes and protective, as opposed to deleterious, immune responses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI057157-11
Application #
8437240
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
11
Fiscal Year
2013
Total Cost
$458,479
Indirect Cost
$74,559
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ashbrook, Alison W; Lentscher, Anthony J; Zamora, Paula F et al. (2016) Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection. MBio 7:
Bowles, R D; Karikari, I O; VanDerwerken, D N et al. (2016) In vivo luminescent imaging of NF-κB activity and NF-κB-related serum cytokine levels predict pain sensitivities in a rodent model of peripheral neuropathy. Eur J Pain 20:365-76
Alayli, Farah; Scholle, Frank (2016) Dengue virus NS1 enhances viral replication and pro-inflammatory cytokine production in human dendritic cells. Virology 496:227-36
Bates, John T; Pickens, Jennifer A; Schuster, Jennifer E et al. (2016) Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Vaccine 34:950-6
Fibriansah, Guntur; Tan, Joanne L; Smith, Scott A et al. (2015) A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 6:6341
de St Maurice, Annabelle; Grijalva, Carlos G; Fonnesbeck, Christopher et al. (2015) Racial and Regional Differences in Rates of Invasive Pneumococcal Disease. Pediatrics 136:e1186-94
Roberts, Lydia M; Ledvina, Hannah E; Tuladhar, Shraddha et al. (2015) Depletion of alveolar macrophages in CD11c diphtheria toxin receptor mice produces an inflammatory response. Immun Inflamm Dis 3:71-81
Smith, Scott A; Silva, Laurie A; Fox, Julie M et al. (2015) Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host Microbe 18:86-95
Pulendran, Bali (2015) The varieties of immunological experience: of pathogens, stress, and dendritic cells. Annu Rev Immunol 33:563-606
Price, Aryn A; Sampson, Timothy R; Ratner, Hannah K et al. (2015) Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc Natl Acad Sci U S A 112:6164-9

Showing the most recent 10 out of 375 publications